For its Asian operations, Zug-based cryptobank Seba has named former Credit Suisse and Barclays investment banker Sam Lin as CEO Asia. With over 15 years of experience in investment banking at Credit Suisse and Barclays, Sam is a highly experienced wealth management practitioner. He is also a business leader in the development and implementation of institutional-grade financial technology solutions. He was a former Executive Director and CFO of a leading Fintech company listed on NASDAQ, which provides a platform for integrating and personalizing financial services across Southeast Asia to over 68 million users; Sam raised USD 300 million in pre-IPO funding for the company. The FINMA licenced Swiss Bank providing a seamless, secure, and easy-to-use bridge between digital and traditional assets, seeks to strengthen its status as a leader in the provision of digital asset banking services in Asia.
9T Labs: CTO, Sales Managers For Italy And Dach Regions
As 9T Labs AG, scales up and prepares for the commercial launch of its hybrid 3D printing technology for producing structural carbon fibre-reinforced thermoplastic composite parts, the company has expanded its executive team with Fabian Pusch as chief technology officer (CTO) and its commercial team with Arne Büttner, sales manager for the DACH (Germany, Austria, Switzerland) region and Andrea Borlenghi, sales manager-Italy. After leaving his position as head of injection moulding technology, Fabian spent six years at Geberit AG, as head of testing at plastic machinery OEM KraussMaffei’s Netstal-Maschinen AG division. Büttner was previously at AFPT GmbH (Dörth, Germany), a leading supplier of laser-assisted tape placement and winding equipment, while Borlenghi has previously led three positions as business territory manager-Italy and Eastern region and country manager-Italy at Roboze S.p.A. (Bari, Italy), which has developed a high-performance polymer additive printer technology.
Properti appoints new COO
Umut Sentürk has is the new Chief Operating Officer of Properti AG. With the addition of Sentürk, Properti responds to the high growth dynamics as a result of the planned European expansion and the increasingly demanding market in the residential ecosystem. Sentürk has 14 years of experience in the industry, of which he worked in a management position in real estate management for about seven years. In addition, he is currently completing his MAS in Real Estate Management at the Bern University of Applied Sciences BFH and worked part-time for about five years as a real estate consultant for the homeowners association of Burgdorf and Trachselwald.
iOnctura with VP Finance and Chief Business Officer
iOnctura SA, a clinical-stage oncology company, targeting core resistance and relapse mechanisms at the tumour-stroma-immune interface, has appointed David Seeberger as Vice-president, Finance and Sean A. MacDonald as Chief Business Officer. Seeberger has extensive experience in publicly-listed growth-oriented biotech and medtech companies. Before taking charge of global finance operations at iOnctura, he served as VP Head of Finance Europe at NASDAQ listed bluebird bio. He held senior financial positions at Aegerion Pharmaceuticals, InterMune Corporation and Stryker Corporation. MacDonald brings a wealth of corporate management and business development experience accumulated over a 20-year career in private and public biotech companies in both Europe and North America. He was CEO of Corbin Therapeutics, Head of Business Development at Cosmo Pharmaceuticals (COPN: SIX) and before that VP Global Corporate and Business Development at Pharmascience Inc. He retains a position as Chairman of the Board of Directors at Edesa Biotech Inc (EDSA: NASDAQ).
MoonLake Immunotherapeutics makes two executive appointments
MoonLake, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, welcomed Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO. MoonLake aims to optimize and accelerate the “pipeline within a product” development of the potentially best-in-class Tri-specific Nanobody® Sonelokimab, which was in-licensed from Merck KGaA, Darmstadt, Germany, in May 2021. Santos da Silva was previously Senior Partner at McKinsey & Company, Inc. For almost 15 years, Jorge was a leader in McKinsey’s Pharmaceutical & Medical Products Practice and in the Company’s Zurich office. He led several key groups at McKinsey over the last decade, including the Biotech group and the Biosimilars group, leading the consultancy’s thinking in several biotech-related topics. Over the years, he advised international biopharma and biotechs, on corporate and business-unit strategy, commercial operating models, R&D, organizational design, M&A, joint ventures, and marketing and sales.
Bodenstedt was previously a Partner at McKinsey & Company and brings deep experience in the biopharmaceutical industry focusing on finance and commercial strategy. At McKinsey, Mr. Bodenstedt served diverse clients, ranging from pre-revenue biotechs to large global pharmaceutical companies. He was a key advisor on many industry-shaping transactions on the sell- and buy-side. He worked closely with senior executives on financing, M&A, BD&L, portfolio strategy, and go-to-market strategy and execution.